SMART Medical Review Type 3c Diabetes: Bridging the Diagnostic and Therapeutic Gap in Pancreatogenic Diabetes
DOI:
https://doi.org/10.69734/k2qsv984Keywords:
type 3c diabetes, T3cDM, pancreatogenic diabetes, pancreatic exocrine insufficiency, exocrine pancreatic insufficiency, chronic pancreatitis, secondary diabetes mellitus, type 2 diabetes, recurrent acute pancreatitis, T2DMAbstract
Type 3c diabetes mellitus (T3cDM), also known as pancreatogenic diabetes, arises from diseases affecting the exocrine pancreas and is frequently misclassified as type 1 or type 2 diabetes mellitus. Despite accounting for an estimated 5–10% of diabetes cases in Western populations, T3cDM remains underrecognized in clinical practice. It encompasses a heterogeneous group of conditions, including chronic pancreatitis, pancreatic cancer, cystic fibrosis, and pancreatic surgery, each with distinct implications for metabolic and nutritional management.
The clinical presentation of T3cDM often involves both insulin deficiency and exocrine pancreatic insufficiency, leading to complex challenges in glycemic control and increased risk for micronutrient deficiencies. Misclassification can result in inappropriate treatment strategies and poorer outcomes. Recognizing the unique pathophysiology of T3cDM is essential for tailoring therapy that addresses both endocrine and exocrine dysfunction.
Early diagnosis and a multidisciplinary approach are critical to optimize glucose management, nutritional status, and long-term health outcomes in this population. Greater awareness and clearer diagnostic criteria are needed to ensure patients with T3cDM receive timely and appropriate care.
References
Woodmansey C, McGovern AP, McCullough KA, Whyte MB, Munro NM, Correa AC, et al. Incidence, demographics, and clinical characteristics of diabetes of the exocrine pancreas (type 3c): a retrospective cohort study. Diabetes Care. 2017;40(11):1486-93.
Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 1997;20(7):1183-97.
Petrov MS. DIAGNOSIS OF ENDOCRINE DISEASE: Post-pancreatitis diabetes mellitus: prime time for secondary disease. Eur J Endocrinol. 2021;184(4):R137-r49.
Cho J, Petrov MS. Pancreatitis, pancreatic cancer, and their metabolic sequelae: projected burden to 2050. Clin Transl Gastroenterol. 2020;11(11):e00251.
Zhi M, Zhu X, Lugea A, Waldron RT, Pandol SJ, Li L. Incidence of new onset diabetes mellitus secondary to acute pancreatitis: a systematic review and meta-analysis. Front Physiol. 2019;10:637.
Yadav D, Whitcomb DC, Tang G, Slivka A, Bellin M. Autoimmunity may explain diabetes in a subset of patients with recurrent acute and chronic pancreatitis: a pilot study. Clin Gastroenterol Hepatol. 2023;21(1):226-8.e1.
Bellin MD, Whitcomb DC, Abberbock J, Sherman S, Sandhu BS, Gardner TB, et al. Patient and disease characteristics associated with the presence of diabetes mellitus in adults with chronic pancreatitis in the United States. Am J Gastroenterol. 2017;112(9):1457-65.
Talukdar R, Sasikala M, Pavan Kumar P, Rao GV, Pradeep R, Reddy DN. T-Helper cell–mediated islet inflammation contributes to β-cell dysfunction in chronic pancreatitis. Pancreas. 2016;45(3):434-42.
Nordmann TM, Dror E, Schulze F, Traub S, Berishvili E, Barbieux C, et al. The role of inflammation in β-cell dedifferentiation. Scientific Reports. 2017;7(1):6285.
Moran A, Brunzell C, Cohen RC, Katz M, Marshall BC, Onady G, et al. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care. 2010;33(12):2697-708.
Goodarzi MO, Nagpal T, Greer P, Cui J, Chen YI, Guo X, et al. Genetic risk score in diabetes associated with chronic pancreatitis versus type 2 diabetes mellitus. Clin Transl Gastroenterol. 2019;10(7):e00057.
Permert J, Ihse I, Jorfeldt L, von Schenck H, Arnqvist HJ, Larsson J. Pancreatic cancer is associated with impaired glucose metabolism. Eur J Surg. 1993;159(2):101-7.
Hart PA, Bellin MD, Andersen DK, Bradley D, Cruz-Monserrate Z, Forsmark CE, et al. Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer. Lancet Gastroenterol Hepatol. 2016;1(3):226-37.
Wasserfall CH, Forsmark CE, Li S, Li L, Hart PA, Goodarzi MO, et al. Type 1 diabetes autoantibodies in acute, recurrent acute, and chronic pancreatitis. Diabetes. 2025;74(9):1603-12.
Juza A, Kołodziej-Spirodek L, Gutkowski K, Partyka M, Dąbrowski M. Distinguishing exocrine pancreas disease-associated diabetes from type 2 diabetes based on anthropometric and metabolic parameters. World J Diabetes. 2025;16(2):95102.
Dranka-Bojarowska D, Lekstan A, Olakowski M, Jablonska B, Lewinski A, Musialski P, et al. The assessment of serum concentration of adiponectin, leptin and serum carbohydrate antigen-19.9 in patients with pancreatic cancer and chronic pancreatitis. J Physiol Pharmacol. 2015;66(5):653-63.
Bao Y, Giovannucci EL, Kraft P, Stampfer MJ, Ogino S, Ma J, et al. A prospective study of plasma adiponectin and pancreatic cancer risk in five US cohorts. J Natl Cancer Inst. 2013;105(2):95-103.
Hart PA, Kudva YC, Yadav D, Andersen DK, Li Y, Toledo FGS, et al. A reduced pancreatic polypeptide response is associated with new-onset pancreatogenic diabetes versus type 2 diabetes. J Clin Endocrinol Metab. 2023;108(5):e120-e8.
Cui Y, Andersen DK. Pancreatogenic diabetes: special considerations for management. Pancreatology. 2011;11(3):279-94.
Beyer G, Habtezion A, Werner J, Lerch MM, Mayerle J. Chronic pancreatitis. The Lancet. 2020;396(10249):499-512.
Whitcomb DC, Buchner AM, Forsmark CE. AGA clinical practice update on the epidemiology, evaluation, and management of exocrine pancreatic insufficiency: expert review. Gastroenterology. 2023;165(5):1292-301.
Bruggeman BS, Schatz DA. Type 1 diabetes: a disorder of the exocrine and endocrine pancreas. J Cell Immunol. 2023;5(4):120-6.
Hardt PD, Hauenschild A, Nalop J, Marzeion AM, Jaeger C, Teichmann J, et al. High prevalence of exocrine pancreatic insufficiency in diabetes mellitus. A multicenter study screening fecal elastase 1 concentrations in 1,021 diabetic patients. Pancreatology. 2003;3(5):395-402.
Duggan SN, Ewald N, Kelleher L, Griffin O, Gibney J, Conlon KC. The nutritional management of type 3c (pancreatogenic) diabetes in chronic pancreatitis. Eur J Clin Nutr. 2017;71(1):3-8.
Domínguez-Muñoz JE, Phillips M. Nutritional therapy in chronic pancreatitis. Gastroenterol Clin North Am. 2018;47(1):95-106.
Perano SJ, Couper JJ, Horowitz M, Martin AJ, Kritas S, Sullivan T, et al. Pancreatic enzyme supplementation improves the incretin hormone response and attenuates postprandial glycemia in adolescents with cystic fibrosis: a randomized crossover trial. J Clin Endocrinol Metab. 2014;99(7):2486-93.
Knop FK, Vilsbøll T, Larsen S, Højberg PV, Vølund A, Madsbad S, et al. Increased postprandial responses of GLP-1 and GIP in patients with chronic pancreatitis and steatorrhea following pancreatic enzyme substitution. Am J Physiol Endocrinol Metab. 2007;292(1):E324-30.
Schuetz P, Fehr R, Baechli V, Geiser M, Deiss M, Gomes F, et al. Individualised nutritional support in medical inpatients at nutritional risk: a randomised clinical trial. Lancet. 2019;393(10188):2312-21.
Goodarzi MO, Petrov MS. Diabetes of the exocrine pancreas: implications for pharmacological management. Drugs. 2023;83(12):1077-90.
Löhr JM, Dominguez-Munoz E, Rosendahl J, Besselink M, Mayerle J, Lerch MM, et al. United European Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis (HaPanEU). United European Gastroenterol J. 2017;5(2):153-99.
Sadeghi N, Abbruzzese JL, Yeung SC, Hassan M, Li D. Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res. 2012;18(10):2905-12.
Juel CTB, Lund A, Andersen MM, Hansen CP, Storkholm JH, Rehfeld JF, et al. The GLP-1 receptor agonist lixisenatide reduces postprandial glucose in patients with diabetes secondary to total pancreatectomy: a randomised, placebo-controlled, double-blinded crossover trial. Diabetologia. 2020;63(7):1285-98.
Phillip M, Nimri R, Bergenstal RM, Barnard-Kelly K, Danne T, Hovorka R, et al. Consensus recommendations for the use of automated insulin delivery technologies in clinical practice. Endocrine Reviews. 2022;44(2):254-80.
Jose JR, Shankar T, Arora P, S P, Jayachandran S. Diabetic Ketoacidosis: a rare complication of type 3c diabetes. Cureus. 2024;16(4):e57873.
Oh HC, Kwon CI, El H, II, Easler JJ, Watkins J, Fogel EL, et al. Low serum pancreatic amylase and lipase values are simple and useful predictors to diagnose chronic pancreatitis. Gut Liver. 2017;11(6):878-83.
Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015;12(3):e1001779.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 SMART-MD Journal of Precision Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Journal information